TC BioPharm LtdNASDAQ:TCBP
- LAST PRICE1.5700
- TODAY'S CHANGE (%)0.1000 (6.8027%)
- Bid / Lots1.5600/ 6
- Ask / Lots1.5700/ 4
- Open / Previous Close1.5200 / 1.4700
- Day Range
- 52 Week Range
- Volume142,101
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TCBP |
|---|---|---|
| 09:32 ET | 5516 | 1.5764 |
| 09:34 ET | 145 | 1.4851 |
| 09:41 ET | 235 | 1.4825 |
| 09:43 ET | 200 | 1.56 |
| 09:45 ET | 500 | 1.49 |
| 09:48 ET | 2000 | 1.4915 |
| 09:52 ET | 200 | 1.5182 |
| 09:59 ET | 650 | 1.5139 |
| 10:01 ET | 6420 | 1.53 |
| 10:12 ET | 362 | 1.53 |
| 10:14 ET | 1830 | 1.55 |
| 10:19 ET | 200 | 1.5503 |
| 10:32 ET | 6850 | 1.57 |
| 10:33 ET | 200 | 1.55 |
| 10:35 ET | 4031 | 1.541 |
| 10:37 ET | 159 | 1.525 |
| 10:46 ET | 200 | 1.58 |
| 10:48 ET | 850 | 1.5796 |
| 10:50 ET | 392 | 1.58 |
| 11:08 ET | 314 | 1.5217 |
| 11:11 ET | 9243 | 1.62 |
| 11:15 ET | 10700 | 1.59 |
| 11:18 ET | 2500 | 1.59 |
| 11:20 ET | 5630 | 1.6 |
| 11:22 ET | 9088 | 1.59 |
| 11:26 ET | 200 | 1.6082 |
| 11:29 ET | 100 | 1.6128 |
| 11:31 ET | 400 | 1.5803 |
| 11:33 ET | 500 | 1.57 |
| 11:45 ET | 300 | 1.59 |
| 11:47 ET | 1880 | 1.5615 |
| 12:02 ET | 8000 | 1.6099 |
| 12:05 ET | 269 | 1.56 |
| 12:14 ET | 500 | 1.6052 |
| 12:20 ET | 500 | 1.5788 |
| 12:27 ET | 100 | 1.6 |
| 12:30 ET | 100 | 1.6 |
| 12:39 ET | 600 | 1.59 |
| 12:43 ET | 1500 | 1.5728 |
| 12:45 ET | 827 | 1.6 |
| 12:54 ET | 700 | 1.6 |
| 12:56 ET | 18187 | 1.65 |
| 01:03 ET | 230 | 1.6025 |
| 01:06 ET | 121 | 1.62 |
| 01:12 ET | 600 | 1.64 |
| 01:14 ET | 955 | 1.6399 |
| 01:21 ET | 12004 | 1.57 |
| 01:30 ET | 1027 | 1.57 |
| 01:44 ET | 850 | 1.5603 |
| 01:51 ET | 250 | 1.5769 |
| 02:00 ET | 100 | 1.5601 |
| 02:02 ET | 173 | 1.56 |
| 02:06 ET | 100 | 1.59 |
| 02:09 ET | 376 | 1.5899 |
| 02:11 ET | 125 | 1.5899 |
| 02:15 ET | 270 | 1.5866 |
| 02:20 ET | 499 | 1.59 |
| 02:24 ET | 843 | 1.59 |
| 02:27 ET | 548 | 1.6 |
| 02:40 ET | 320 | 1.5999 |
| 02:42 ET | 995 | 1.57 |
| 02:44 ET | 153 | 1.59 |
| 02:45 ET | 247 | 1.5708 |
| 02:47 ET | 1032 | 1.5725 |
| 02:49 ET | 100 | 1.57 |
| 02:58 ET | 469 | 1.57 |
| 03:14 ET | 100 | 1.57 |
| 03:27 ET | 531 | 1.57 |
| 03:30 ET | 398 | 1.57 |
| 03:36 ET | 657 | 1.56 |
| 03:41 ET | 399 | 1.57 |
Apr 4, 2024
DJ TC BioPharm Shares Rise 63% After Letter Intent to Buy Cancer Therapy Assets, from 1:12PM ET on Thursday Apr 04, 2024 by Dow Jones
1:12PM ET on Thursday Apr 04, 2024 by Dow JonesTCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies, from 8:32AM ET on Thursday Apr 04, 2024 by Dow Jones
8:32AM ET on Thursday Apr 04, 2024 by Dow Jones*DJ TCBP Announces Execution Of Non-Binding Letter Of Intent For Acquisition Of NK Platform Technologies >TCBP, from 8:32AM ET on Thursday Apr 04, 2024 by Dow Jones
8:32AM ET on Thursday Apr 04, 2024 by Dow Jones
Apr 2, 2024
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process, from 8:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TC BioPharm Ltd | 4.7M | 0.0x | --- |
Enzon Pharmaceuticals Inc | 5.8M | 66.7x | -60.21% |
Goldenwell Biotech Inc | 5.8M | -48.0x | --- |
CeCors Inc | 6.0M | 0.0x | --- |
Actavia Life Sciences Inc | 6.0M | -1.0x | --- |
First Wave BioPharma Inc | 6.1M | 0.0x | --- |
Company Information
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
Contact Information
- Headquarters
- Maxim 1, 2 Parklands WayHONITON, United Kingdom ML1 4WR
- Phone
- 141-433-7557
- Fax
- ---
Executives
- Independent Non-Executive Chairman of the Board
- Arlene Morris
- Chief Executive Officer
- Bryan Kobel
- Chief Financial Officer, Director
- Martin Thorp
- Non-Executive Independent Director
- Mark Bonyhadi
- Non-Executive Independent Director
- James Culverwell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.7M |
|---|---|
Revenue (TTM) | $3.6M |
Shares Outstanding | 159.8K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-684.36 |
Book Value | $3.25 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
